NOTE

🌱 created from: acute lymphoblastic leukemia

eln_guideline_2024

• Morphology of ALL

• Immunophenotyping of ALL

• Cytogenetics/Molecular genetics of ALL

• Establish MRD assay of ALL

• Clinical features of ALL

• Extended genomics, Biobanking

• Clinical: ALL, LL, CNS+or-

• Subsets and subtypes：

  • Ph/BCR：ABL1+，
  • B/T-precursor Ph/BCR:ABL1-，
  • KMT2A rearrangements

1.Gökbuget N, Boissel N, Chiaretti S, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1891-1902. doi:10.1182/blood.2023020794

2.Gökbuget N, Boissel N, Chiaretti S, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903-1930. doi:10.1182/blood.2023023568